Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2013 · 63 citations · 22 references
MedicineMolecular BiologyNeurologyEpigeneticsMolecular NeurobiologyMolecular NeuroscienceAmyotrophic Lateral SclerosisDna MethylationDna Methylation ProfilingEpigenetic Biomarker AnalysisNeurodegenerative DiseasesNeurodegenerative DisordersAge-associated Dna Methylation ChangesAmyotrophic Lateral Sclerosis EpigeneticsDna Methylation BiomarkersEpigenetic SignaturesGlobal Dna MethylationIsotope DilutionIsotope Dilution Mass SpectrometryMotor Neuron Pathophysiology
ALS is a heterogeneous disease that is not well understood. Epigenetic rearrangements are important in complex disorders including motor neuron diseases. The aim of this study was to determine whether whole-blood DNA methylation (DNA MET %) is a potential modifier of age at onset in ALS. DNA MET % was measured as incorporation of [(3)H]dCTP following HpaII cut in 96 ALS patients and 87 controls, comprising: early-onset (< 55 years of age) and late-onset (> 74 years of age). Methionine (Met) and homocysteine (Hcy) plasma levels were assessed by liquid chromatography selected reaction monitoring coupled with isotope-dilution mass spectrometry. Results showed that DNA MET % was increased in ALS patients independently of age of onset. Compared to the other three groups, Hcy plasma levels were reduced in early-onset ALS patients but Met levels were similar. ROC analysis reported Met levels and DNA MET %, respectively, with a slight and moderate discriminative power. In conclusion, increased DNA MET % is a possible marker of epigenetic dysfunction in ALS independently of age of onset. Further studies dissecting biological determinants of phenotypic complexity in ALS may help in developing successful therapeutic strategies.
22
Age-Specific Epigenetic Drift in Late-Onset Alzheimer's Disease
Sun-Chong Wang, Beatrice Oelze, Axel Schumacher · PLoS ONE · 2008 · 469 citations · Full text